Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + bendamustine + dexamethasone in systemic AL amyloidosis ineligible for transplant
2008-007125-39Phase 2Terminated
- Sponsor
- Klinik f. Innere Med. Fachabteilung Hämatologie
- Start
- Mar 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide, bendamustine and dexamethasone in light-chain amyloidosis, sponsored by Klinik f. Innere Med. Fachabteilung Hämatologie. Primary endpoints: Feasibility and objective response rate and Optimal dosage determination. Started Mar 2009; status: terminated.
02
Drugs
lenalidomidebendamustinedexamethasone
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2008-007125-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007125-39.